Bayer is trading at €46.02 (-4.03%) amid broader European market weakness.
- European shares broadly fell on October 1 as investors turned risk-averse amid multi-year-high global bond yields; the STOXX 600 was down 1% in morning trading.
- Bayer’s FDA Priority Review news concerned Lynkuet and was announced September 28, so it does not clearly explain the October 1 decline.